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Background: An actual clinical trial showed the effect of low dose radiotherapy in painful heel spur (plantar
fasciitis) with single doses of 1.0 Gy and total doses of 6.0 Gy applied twice weekly. Furthermore, a lot of animal
experimental and in vitro data reveals the effect of lower single doses of 0.5 Gy which may be superior in order to
ease pain and reduce inflammation in patients with painful heel spur. Our goal is therefore to transfer this
experimentally found effect into a randomized multicenter trial.
Study design/methods: This was a controlled, prospective, two-arm phase III-multicenter trial. The standard arm
consisted of single fractions of 1.0 Gy applied two times a week, for a total dose of 6.0 Gy (total therapy time: 3 weeks).
The experimental arm consisted of single fractions of 0.5 Gy applied 3 times a week, for a total dose of 6.0 Gy (total
therapy time: 4 weeks). Following a statistical power calculation, there were 120 patients for each investigation arm.
The main inclusion criteria were: age > = 40 years, clinical and radiologically diagnosed painful heel spur (plantar
fasciitis), and current symptoms for at least 6 months. The main exclusion criteria were: former local trauma, surgery or
radiotherapy of the heel; pregnant or breastfeeding women; and a pre-existing severe psychiatric or psychosomatic
disorder.
Methods: After approving a written informed consent the patients are randomized by a statistician into one of the trial
arms. After radiotherapy, the patients are seen after six weeks, after twelve weeks and then every twelve weeks up to
48 weeks. Additionally, they receive a questionnaire every six weeks after the follow-up examinations up to 48 weeks.
The effect is measured using the visual analogue scale of pain (VAS), the calcaneodynia score according to Rowe and
the SF-12 score. The primary endpoint is the pain relief three months after therapy. Patients of both therapy arms with
an insufficient result are offered a second radiotherapy series applying the standard dose (equally in both arms).
This trial protocol has been approved by the expert panel of the DEGRO as well as by the Ethics committee of the
Saarland Physicians’ chamber.
Trial registration: Current trial registration at German Clinical Trials Register with the number DRKS00004458
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Principles
The painful heel spur was first described by Plettner
et al. [1] summarizing radiological findings of exostoses
situated at the plantar part of the calcaneus or at the in-
sertion point of the plantar aponeurosis. Various authors
give values for the incidence of 8 to 88% of an unse-
lected population [2-4]. Risk factors described are old
age, obesity, and foot or leg deformities. Histopatho-
logical findings are fibroostosis promoted by mechanical
stress to the plantar aponeurosis, slowly and continu-
ously growing into its insertion region [5]. In a more
chronical stage of the disease, the degenerative changes
cause a local inflammation of the plantar aponeurosis
(plantar fasciitis), which should be well differentiated
from – for example – rheumatoid arthritis.
Clinical symptoms
Radiological diagnosed heel spurs often are completely
asymptomatic. 16% of the patients with painful heel spurs
have local pain getting worse over weeks to months under
the heel, which can further extend to the foot or the lower
limb. Local pressure to the medial edge of the calcaneus
may be painful [5]. To our own experience, most of the
symptomatic patients cannot stand or walk for a long
time, the pain may be even worse during the first minutes
of rest after a walk.
Radiological findings
Conventional lateral x-rays of the calcaneus are gold
standard in the diagnosis of a heel spur. They show a
calcified spur at the inferior side of the calcaneus. The
intensity of pain does not correlate to the radiological
size of the spur. Additionally a local ultrasound examin-
ation can be performed in order to examine the swelling
and irritation of the plantar fascia. A bone scan may be
positive showing local inflammation which remits after
successful therapy. A good diagnostic alternative to the
scintigraphy seems to be the MR imaging because of its
superior soft tissue contrast and good anatomical reso-
lution. Typical in MR imaging is a thickening of the
fascia and a surrounding soft tissue edema. In contrast-
medium enhanced sequences intratendinous signal alter-
ations of the fascia are often found.
Conventional therapy methods
Ice, heat, ultrasound, radiofrequency, laser beams and
extracorporal shock wave therapy have been applied, all of
them with confined clinical success. Steroids and local an-
esthetics injected into the plantar fascia and oral analgetic
medication (NSAID) are often prescribed. Immobilization
of the foot using special splints and adjustable shoes were
applied. Physiotherapy was performed [2,3]. Iontophoresis
using dexamethasone was found to be superior toiontophoresis with placebo (NaCl) [6]. Extracorporal
shock wave therapy yielded a complete pain relief in up to
68% of the patients [7]. A randomized trial published by
Batt et al. [8] showed that better results were recorded by
adding local immobilization of the foot in maximum dor-
sal flexion during night to a standard therapy (NSAID,
splints) compared to this standard therapy alone. Accord-
ing to Powell et al. [9], a splint applied immediately after
diagnosis was as effective as an application one month
later. In further randomized trials mechanical therapy
using ortheses was found better than application of local
analgesics only, silicon shoe inserts were found superior to
other shoe adjustments [10], functional foot ortheses were
found to be more advantageous than simple heel splints
[11]. Most of these methods and their results have been
summarized in an actual Cochrane review [12].
Surgery
It is general consensus that patients will only undergo sur-
gery in case conservative therapy methods have not yielded
sufficient pain relief. Heider et al. [13] report good to excel-
lent results in 26 out of 28 feet after open surgery.
Favourable results were recorded as well using endoscopic
release of the plantar fascia [14]. Nevertheless, complications
like fractures of the calcaneus [15] as well as negative
biomechanical consequences of plantar fascia relief have
been reported [16].
Radiotherapy – experimental data
The anti-inflammatory effect of radiation therapy has
been known for a long time and has been reported in
numerous publications. Nevertheless, the exact ultra-
structural mechanism is still unclear. Some of the more
ancient models are discussed in [17-20].
In animal experiments, Steffen et al. noticed anti-
inflammatory effects of low-dose radiotherapy (6Gy) on
antigen-induced arthritis in rabbits [21]. Hildebrandt
et al. have shown that low-dose radiation effects can be
explained by an influence on molecular mechanisms and
inflammation mediators [22-24]. New in-vitro investiga-
tions by Hildebrandt et al. 2003 and Rödel et al. 2002
[25,26] show a reduced iNOS protein expression and
NO-production in macrophages. Latter investigation could
also point that single doses of 0.3-0,5 Gy lead to a local
maximum of apoptosis in macrophages and a reduced
E-selectin-presentation on endothelium cells combined
with an enhanced expression of TGFβ1 [26]. Hildebrand
could also show in vitro that depending on modulation of
cytokine-stimulated E-selectin-presentation leukocytes
could less adhere to endothelium especially with single
doses of 0.3-0.6 Gy. This finding also underlines the
anti-inflammatory effect of low-dose therapy [27]. Add-
itionally Gaipl et al. (2009) revealed a maximum of
activity-induced cell death in polymorphnuclear cells
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Further anti-inflammatory effects of low-dose radiother-
apy seem to be a reduced CCL-20-chemokine-expression,
a reduced adhesion of granulocytes to endothelium cells
and an enhanced activity of AP-1 DNA ligation strength
[29,30]. An actual review article points out the induction
of expression of the X-linked inhibitor of apoptosis and
TGFβ1 and the reduced expression of E- and L-selectin,
Interleukin-1 and CCL20 through macrophages and poly-
morphnuclear cells using single doses between 0.5 and
0.7 Gy [31]. Another new review article shows additionally
high levels of hemioxigenase 1 (HO-1) and heat shock pro-
tein 70 (HSP 70) with maximum single doses of 0.5 Gy [32].
Radiotherapy – clinical results
Numerous retrospective trials have shown that low-dose
radiotherapy for painful heel spur has a good analgesic
effect, pain relief has been noticed in 65–90% of the pa-
tients [17,20,33-36]. However, a certain placebo effect is
still under discussion [33]. Goldie et al. examined this ef-
fect in 399 patients with painful conditions of the loco-
motor system. They found a response in 60% of the
patients whether irradiated or not; these results made
the effect of radiotherapy questionable [37]. The trial,
however, has been criticized because of missing clearly
defined endpoints: furthermore the therapy was started
in an acute stage of the diseases and the authors did not
wait for spontaneous pain remissions. In the meantime,
several more modern trials have shown the analgetic ef-
fect of radiotherapy. Seegenschmiedt et al. [2] performed
a randomized trial treating 141 patients (170 heels) for
painful heel spur using orthovoltage, comparing three
radiotherapy schedules: 1 Gy/fraction up to 12 Gy,
0.3 Gy/fraction up to 3 Gy and 0.5 Gy/fraction up to
5 Gy. The overall complete pain relief was reported in
67–72% of the patients. The best results were seen after
a total dose of 5 Gy. These results were confirmed by
Schäfer et al. using a telecobalt machine, they achieved a
complete pain relief in 58% [33]. Heyd et al. used 6 MV
photon beams of a linear accelerator, they noticed a fre-
quency of pain relief of 69% [4]. The same author group
published a prospective randomized trial recently [38]
comparing the effect of a total dose of 3 Gy (single frac-
tion 0.5 Gy twice weekly) to that of a total dose of 6 Gy
(single fraction 1 Gy twice weekly). Radiotherapy was re-
ported very efficient however a dependency from dose
could not be noticed. Mücke et al. looked for prognostic
factors for pain relief in a multicenter trial [39]. They
found an overall response in 60.9%. Significant favourable
prognostic factors for pain relief were a patient's age over
58 years, the use of megavoltage techniques and the num-
ber of therapy series required. Niewald et al. showed in ac-
tual prospective study that a total dose of 6 Gy with single
doses of 1 Gy twice weekly is much more effective than atotal dose of 0.6 Gy with single doses of 0.1 Gy concerning
analgetic effect and showed that a total doses of 6 Gy
makes this effect durable for at least 1 year [40]. After the
start of this trial, Ott et al. [41] published their trial com-
paring the effect of six single doses of 1Gy (total dose
6Gy) to six single doses of 0.5Gy (total dose 3Gy). They
found no difference between the arms.
Radiotherapy – side effects and risks
Physicians of other specialities sometimes refuse to refer pa-
tients to radiotherapy because of the fear of local side effects
such as impairment of gonad function or induction of malig-
nancies. Neither local toxicity nor tumour induction have
been reported yet [34,42,43]. The dose to the gonads is com-
parable to that after radiodiagnostic interventions [20,44-46].
Radiotherapy – conclusion
Summarizing the data taken from the literature it can be
concluded that low-dose radiotherapy for painful heel
spur with total doses ranging from 3–12 Gy is effective
in the vast majority of patients and the side effects are
negligible. However, a placebo effect cannot be excluded
totally. Thus, randomized trials (like the present one)
using defined criteria and scores are necessary [4].
Nevertheless, outside Europe there is a general reluctance
against radiotherapy for benign disease. One reason may be
that trials comparing conservative approaches, radiotherapy
and surgery are very rare.
Much more important to our current trial is, however, to
translate the experimental findings that lower single doses
may be more advantageous than higher ones into the clinic
comparing two patient groups with the same total dose
and different fractionation schedules (1.0 Gy vs. 0.5 Gy).
General therapy remarks
At the moment a lot of competing therapy approaches
for painful heel spur are processed. One can summarize
them to conventional/conservative approaches, radiother-
apy and surgery. Up to now a lack of definite evidence is
still existing which method to choose. Additionally and
despite all experimental and clinical findings concerning
radiotherapy for painful heel spur a general reluctance




 clinical evidence of painful plantar heel spur with an
anamnesis during ≥ 6 month
 radiological proof of the spur (in conventional
radiography)
 typical clinical symptomatic with tenderness on
palpation at medial tuber calcanei
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walking distance
 Karnofsky performance index ≥ 70%
 age ≥ 40 years
 written informed consent
Exclusion criteria
 previous radiotherapy and/or trauma to the foot
region (i.e. fracture, tendon rupture)
 rheumatic, arterial or venous diseases, manifest
lymphatic edema of the concerned foot/leg
 pregnancy, breastfeeding (regulatory reasons)
 severe psychiatric disorder
 statutory maintenance in medical affairs by relativesInformed consent
Before enrolment into the study, an informed consent is
to be obtained from all patients after detailed informa-
tion and explanations concerning:
 the positive and negative aspects of the therapy
(i.e. toxicity),
 alternative therapy methods,
 data protection issues,
 schedule of the study (follow-up examinations, time
frame, etc.),
 autonomy of choice in participating into the study,
all the time possibility to withdraw the consent
without the need to communicate special reasonsInitial diagnosis
 Obligate: standardized anamnesis, clinical-
orthopedic examination, lateral x-ray imaging of
metatarsus and heel with diagnosis of heel spur in
the region of tuberculum mediale calcanei at the
dorsal insertion of the plantar aponeurosis
 Facultative: Ultrasound illustrating inflammation of
plantar aponeurosis, bone scan in case of negative
x-ray, MR-tomography to demonstrate the process
of plantar fasciitis or detect further symptoms (i.e. bone
marrow edema).Therapy protocol
After recording anamnesis, clinical-orthopedic investiga-
tion, radiographic confirmation of the diagnosis, check-
ing eligibility criteria and written informed consent,
filling in the SF-12-, Calcaneodynia- and VAS score
forms, patients are randomly assigned to either Arm A
or B of this study. Arm A (standard dose): Total dose of 6Gy, single
fractions of 1 Gy applied two times a week over three
weeks (either Monday/Thursday or Tuesday/Friday)
 Arm B (experimental dose): Total dose of 6 Gy,
single fractions of 0.5 Gy applied three times a week
over 4 weeks (Monday/Wednesday/Friday)
 Consequently, the gap between the fractions within
a week is one to two days.
 Follow-up examinations are performed every six
weeks after radiotherapy filling in the
Calcaneodynia-Score, SF-12 questionnaire and
VAS-score. On weeks 6, 12, 24, 36 and 48 after
radiotherapy, the patients get an additional physical
examination, on weeks 18, 30, 42 they only receive
the questionnaires.
In case of persisting or aggravating origin symptoms des-
pite radiotherapy minimum twelve weeks after radiotherapy
patients in both arms are offered a second treatment with
the standard fractionated dose. The ideal time point will be
chosen by the patient and the local radiooncologist to-
gether. Results of these patients are categorized as unsatis-
factory and censored beyond the leaving date of the patient.
Patients wishing the second therapy series later than
12 weeks after therapy will be taken into account in the
final analysis.
After follow-up examination of all 240 patients (120 per
arm) for 48 weeks the study will be closed and the final
data analysis will be performed. Interim analyses will be
performed after enrolment of 120 and 180 patients. In case
of significantly different results in the groups or the publi-
cation of practice changing results from other authors
which lead an ethical reappraisal of this trial the
randomization of new patients will be stopped and the
already randomized patients will get their follow-up exami-
nations up to 48 weeks.
The use of analgesic drugs and physiotherapy is allowed
during the trial. These will be recorded and taken in to ac-
count in the final analysis. Patients having been treated by
shock wave therapy or surgery will be excluded from the
analysis.
Randomization and statistics
Randomization is performed as a block randomization by
the statistician. Patients are assigned randomly to one of
the therapy arms by equal possibility for randomization for
both arms.
According to a previous trial published by Niewald et al.
(40) and an actual statistical calculation before beginning
this study 120 patients are required in each arm and have
to be evaluated over 48 weeks (inclusive a drop-out rate of
10% of the patients) in order to detect a difference of 15%
in VAS and Calcaneodynia-Score with a power of 80%
(error probability of 5%).
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formed using the MEDLOG software package (Fa. Parox,
Münster) after observing the patients for 12 and 48 weeks
and are controlled by the statistician.
Primary endpoints (measured at 12 and 48 weeks after
therapy)
 SF-12 sum score [47,48]
 Calcaneodynia sum score [2,49]
 VAS self-assessment-score
The endpoints will be measured 12 and 48 weeks after
radiotherapy, the results will be compared.
Secondary endpoints
 SF-12 single score
 Calcaneodynia single score
 Event-free interval
Radiotherapy methods
Radiotherapy is performed under orthovoltage conditions
(200–250 kV) or high voltage conditions using a cobalt
unit or high energy photons of linear accelerators (up to 6
MV without bolus, 10 MV with a bolus of 1 cm).
For orthovoltage therapy, a plantar direct field with
tissue equivalent bolus material affixed around the heel
is used (‘Essen technique’). The dose should be standard-
ized to a fix reference point (i.e. in 5 mm tissue depth).
For cobalt units or linear accelerators isocentric lateral
parallel opposing portals are used (isocenter: center of
calcaneus).
The dose is computed either by individual calculation
or by depth- dose curves/charts of the therapy machines.
The target volume should involve the calcaneus, plantar
aponeurosis and the pain point including a safety margin
of 2 cm. Gonads have to be shielded as well as possible.
Quality assurance
Methods to ensure quality are especially:
 Questionnaires are signed for accuracy by physician
and physicist
 Visiting and personally initiation of all participating
centers. Participating centers will additionally been asked
to send x-rays, portal imaging pictures and therapy plans
of randomly selected patients to the study center
 Data entered into database will be checked
independently by two physicians
Ethics
The trial protocol has been approved by the Ethics com-
mittee of the Saarland Physicians’ Chamber (number 14/07 on 09/05/2012). Furthermore, it has been approved
by the board of directors of the DEGRO (German Society
for Radiation Oncology).
Accrual time
Accrual of patients has begun in February, 2013 and is
planned to last three years.
Present status of the trial
In the meantime 120 patients have been enrolled into
study. The interim analysis is under discussion. Besides
Saarland University Medical School, two further centers
are actually enrolling patients.
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